What Is an NDC Swap? 10 Hidden Revenue Leaks in Pharmacy

Distributors frequently ship 100-count bottles when pharmacies order and bill for 500-count packages, creating immediate acquisition cost discrepancies. The reimbursement remains tied to the original NDC code while actual inventory reflects a different package configuration. This mismatch compounds during inventory reconciliation when physical counts don't align with purchasing records. Pharmacies often discover these substitutions weeks after receiving shipments, making retrospective claim corrections difficult. The price-per-unit difference between package sizes can reach 15-30% for common generics.

Wholesalers switch generic manufacturers mid-contract without updating order confirmations, shipping Manufacturer B when invoices reflect Manufacturer A pricing. Reimbursement rates vary significantly between manufacturers for identical molecules, sometimes differing by $5-$20 per prescription. The pharmacy bills insurance using the expected NDC while dispensing from different stock, creating compliance risks during PBM audits. These substitutions often occur during drug shortages when wholesalers source from alternative suppliers. Pharmacies face potential recoupment demands if auditors identify the NDC code mismatch during claims reviews.

Pharmacies bill for 90-day supplies using specific NDC codes but dispense from multiple bottles with different identifiers due to inventory constraints. Insurance reimbursement calculations assume single-source acquisition costs, while actual costs reflect blended pricing from multiple packages. This creates hidden margin erosion of 8-12% on affected prescriptions. The practice becomes particularly problematic with high-cost specialty medications where NDC-specific pricing can vary by hundreds of dollars. Documentation gaps during partial fills make retrospective reconciliation nearly impossible without automated tracking systems.

Pharmacies purchase bulk medications and repackage into unit-dose formats but fail to update billing systems with repackager NDC codes. Claims submitted with manufacturer NDC codes trigger reimbursement rates that don't reflect actual acquisition costs from repackaging suppliers. The price differential reaches 20-40% for commonly repackaged products like unit-dose tablets. PBM audits specifically target repackaging discrepancies, with recoupment rates exceeding 60% when documentation is incomplete. Many pharmacies lack systematic processes to map repackager NDC codes to original manufacturer identifiers.

Pharmacists dispense 20mg tablets when 10mg was ordered due to inventory shortages, adjusting quantity but failing to update NDC codes in billing systems. Reimbursement algorithms calculate payments based on strength-specific pricing, creating overcharges or undercharges depending on relative costs. These drug swap pharmacy errors trigger fraud alerts in PBM monitoring systems when patterns emerge across multiple claims. The strength mismatch also creates clinical documentation gaps that complicate medication therapy management reviews. Automated claim scrubbing catches only 40-50% of strength variations before submission.

Wholesalers substitute biosimilar products for reference biologics without clear invoice differentiation, while pharmacy systems bill using reference product NDC codes. Reimbursement for biosimilars typically runs 15-35% lower than reference products, creating significant revenue leaks on high-cost medications. The substitution often occurs automatically through wholesaler fulfillment systems that prioritize lower-cost alternatives. Pharmacies discover the mismatch only during detailed invoice reconciliation or when patients question product appearance changes. Some PBM contracts include biosimilar payment policies that further reduce reimbursement when proper NDC codes aren't used.

Pharmacies participating in 340B programs dispense discounted inventory to non-eligible patients while billing with 340B acquisition costs, or vice versa. The NDC code remains identical, but acquisition cost basis differs dramatically between 340B and wholesale-acquired inventory. This creates compliance violations and revenue distortions that average $10,000-$25,000 annually for affected pharmacies. Tracking which physical inventory units came from 340B purchases versus wholesale orders requires sophisticated inventory management. Federal audits of 340B programs specifically examine whether billed NDC codes match actual dispensed inventory sources.

Pharmacy technicians select brand-name products from shelves when generic versions were billed due to similar packaging or shelf placement errors. The acquisition cost difference between brand and generic versions ranges from 300-2000% for common medications. Insurance reimbursement based on generic NDC codes covers only a fraction of actual brand product costs. These errors occur most frequently during high-volume periods when staff rely on shelf location rather than verifying NDC codes. The pharmacy absorbs the full cost difference, which can exceed $100 per prescription for certain products.

Pharmacy management systems retain discontinued NDC codes in formularies long after manufacturers cease production, leading to claims submissions with obsolete identifiers. PBMs reject these claims or reimburse at outdated rates that don't reflect current market pricing for replacement products. The rejected claims require resubmission with updated NDC codes, delaying payment by 15-30 days. Many pharmacies lack automated processes to purge discontinued codes and map them to current alternatives. The problem intensifies when wholesalers ship replacement products without clearly indicating NDC changes on invoices.

Pharmacies bill commercial ingredient NDC codes for compounded preparations instead of using compound-specific billing codes or appropriate base ingredient identifiers. Insurance reimbursement algorithms designed for manufactured products don't account for compounding labor and additional ingredients. This results in underpayment of 30-60% compared to proper compounding fee structures. Some PBMs automatically deny claims when compounded quantities don't match standard package sizes associated with billed NDC codes. The practice also creates audit liability when reviewers identify commercially available NDC codes billed for custom compounds.